Commercialization of Gammagard Liquid ERC is expected to begin in 2026. The Food and Drug Administration (FDA) has approved Gammagard Liquid ERC (immune globulin infusion [human] 10% solution) as a ...
Gut microbiota may be the key factor explaining why certain individuals do not respond well to the pneumococcal vaccine-a bacterium that can cause various diseases, such as pneumonia. This conclusion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results